| アブストラクト | Background: Evidence on mortality risks associated with MS-immunotherapies during the SARS-CoV2 pandemic derived thus far mainly from single country experiences. Objective: In this analysis, we aim to determine the frequency of COVID-19 associated fatality reports of patients receiving an MS-immunotherapy as reported to the international Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from February 2020 to March 2021. Methods: In all, 1071 cases for this cross-sectional analysis were retrieved from FAERS and a multivariable logistic regression was performed. We adjusted for sex, age, region, month of report to FDA, immunotherapy-class and additionally for healthcare-system and pandemic-related metrics. Result: Anti-CD20 therapies (60%) followed by sphingosine-1 phosphate modulators (12%) and dimethylfumarat (10%) were reported most frequently. In 50% of the cases, MS-phenotype is not reported, relapsing MS in 35% and progressive MS in 15%. Besides older age (odds ratio [OR]: 1.1; 95% confidence interval [CI]: 1.07-1.13; p < 0.01), anti-CD20 therapies were significantly associated with a higher risk of death (OR: 4.1; 95% CI: 1.17-14.46; p = 0.03), whereas female sex was associated with a reduced mortality risk (OR: 0.4, 95% CI: 0.22-0.72; p < 0.01). Conclusion: Using international open access data and a multidisciplinary approach for risk prediction, we identified an increased mortality risk associated with anti-CD20 therapies, which is in line with national and multi-national cohort studies. |
|---|
| ジャーナル名 | Therapeutic advances in neurological disorders |
|---|
| Pubmed追加日 | 2022/10/15 |
|---|
| 投稿者 | Pistor, Maximilian; Hoepner, Robert; Hoepner, Andreas G F; Lin, Yanan; Jung, Simon; Bassetti, Claudio L; Chan, Andrew; Salmen, Anke |
|---|
| 組織名 | Department of Neurology, Inselspital, Bern University Hospital, University of;Bern, Freiburgstrasse, 3010 Bern, Switzerland.;Bern, Bern, Switzerland.;Department of Banking & Finance, Michael Smurfit Graduate Business School,;University College Dublin, Dublin, Republic of Ireland.;Platform for Sustainable Finance, Department for Financial Stability and Capital;Markets (DG FISMA), European Commission, European Union (EU), Brussels, Belgium. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36237201/ |
|---|
